Mirum's brelovitug meets primary endpoint in Phase 2b AZURE-1 chronic hepatitis delta trial
Mirum's brelovitug meets primary endpoint in Phase 2b AZURE-1 chronic hepatitis delta trial with strong antiviral efficacy
- Phase 2b AZURE-1 trial showed a favorable safety profile for brelovitug in chronic hepatitis delta virus patients.
- Results support continued Phase 3 development of brelovitug for chronic hepatitis delta virus.
- Mirum anticipates a potential U.S. BLA submission for brelovitug in chronic hepatitis delta virus in 2027.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.